Daniel Robert Kuritzkes, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 266 | 2024 | 6819 | 13.160 |
Why?
|
| Drug Resistance, Viral | 110 | 2023 | 842 | 10.110 |
Why?
|
| Anti-HIV Agents | 186 | 2024 | 4430 | 8.510 |
Why?
|
| HIV Infections | 302 | 2024 | 16984 | 8.280 |
Why?
|
| Reverse Transcriptase Inhibitors | 64 | 2023 | 618 | 5.440 |
Why?
|
| HIV Reverse Transcriptase | 33 | 2020 | 212 | 4.510 |
Why?
|
| HIV Fusion Inhibitors | 24 | 2013 | 83 | 3.960 |
Why?
|
| Viral Load | 104 | 2023 | 3285 | 3.700 |
Why?
|
| Lamivudine | 39 | 2021 | 349 | 3.560 |
Why?
|
| Zidovudine | 47 | 2021 | 620 | 2.960 |
Why?
|
| RNA, Viral | 106 | 2024 | 2824 | 2.730 |
Why?
|
| HIV Integrase Inhibitors | 10 | 2023 | 163 | 2.590 |
Why?
|
| Anti-Retroviral Agents | 35 | 2023 | 1766 | 2.580 |
Why?
|
| Antiretroviral Therapy, Highly Active | 45 | 2018 | 1891 | 2.560 |
Why?
|
| Acquired Immunodeficiency Syndrome | 43 | 2023 | 2197 | 2.450 |
Why?
|
| Receptors, CCR5 | 15 | 2016 | 487 | 2.020 |
Why?
|
| Viremia | 20 | 2023 | 703 | 1.990 |
Why?
|
| HIV Envelope Protein gp41 | 17 | 2012 | 304 | 1.850 |
Why?
|
| CD4 Lymphocyte Count | 83 | 2023 | 2556 | 1.730 |
Why?
|
| HIV Integrase | 4 | 2023 | 121 | 1.680 |
Why?
|
| Benzoxazines | 22 | 2020 | 306 | 1.620 |
Why?
|
| Virus Replication | 26 | 2023 | 2423 | 1.560 |
Why?
|
| Piperazines | 22 | 2020 | 2487 | 1.410 |
Why?
|
| HIV | 24 | 2021 | 1578 | 1.390 |
Why?
|
| Drug Resistance, Multiple, Viral | 11 | 2008 | 53 | 1.370 |
Why?
|
| HIV Seropositivity | 9 | 2023 | 954 | 1.330 |
Why?
|
| Pyrrolidinones | 8 | 2014 | 116 | 1.280 |
Why?
|
| Receptors, HIV | 6 | 2016 | 159 | 1.270 |
Why?
|
| Mutation | 76 | 2023 | 29706 | 1.230 |
Why?
|
| HIV Protease Inhibitors | 25 | 2020 | 432 | 1.200 |
Why?
|
| Ritonavir | 24 | 2022 | 326 | 1.160 |
Why?
|
| Virology | 4 | 2010 | 74 | 1.110 |
Why?
|
| Pyrimidines | 15 | 2012 | 2979 | 1.050 |
Why?
|
| Virus Internalization | 6 | 2013 | 491 | 1.020 |
Why?
|
| AIDS Vaccines | 11 | 2023 | 892 | 1.000 |
Why?
|
| Peptide Fragments | 21 | 2016 | 5070 | 0.970 |
Why?
|
| DNA, Viral | 23 | 2021 | 2176 | 0.960 |
Why?
|
| Adenine | 10 | 2021 | 977 | 0.880 |
Why?
|
| CD4-Positive T-Lymphocytes | 32 | 2023 | 4279 | 0.870 |
Why?
|
| Treatment Failure | 27 | 2021 | 2635 | 0.850 |
Why?
|
| Alkynes | 22 | 2020 | 310 | 0.810 |
Why?
|
| Cyclopropanes | 22 | 2020 | 419 | 0.780 |
Why?
|
| Humans | 384 | 2024 | 752411 | 0.770 |
Why?
|
| Drug Resistance, Microbial | 24 | 2004 | 855 | 0.750 |
Why?
|
| Cyclohexanes | 8 | 2013 | 150 | 0.740 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 6 | 2016 | 365 | 0.730 |
Why?
|
| Viral Tropism | 8 | 2016 | 102 | 0.720 |
Why?
|
| Receptors, CXCR4 | 8 | 2016 | 728 | 0.720 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 6 | 2020 | 262 | 0.710 |
Why?
|
| Oxazines | 11 | 2023 | 324 | 0.670 |
Why?
|
| Drug Therapy, Combination | 56 | 2018 | 6479 | 0.650 |
Why?
|
| Salvage Therapy | 5 | 2006 | 1265 | 0.640 |
Why?
|
| Polymerase Chain Reaction | 17 | 2020 | 6058 | 0.630 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2004 | 620 | 0.630 |
Why?
|
| Lymphocyte Activation | 17 | 2020 | 5412 | 0.630 |
Why?
|
| Microbial Sensitivity Tests | 19 | 2016 | 1897 | 0.620 |
Why?
|
| Pyridones | 10 | 2023 | 766 | 0.610 |
Why?
|
| Proviruses | 9 | 2024 | 312 | 0.610 |
Why?
|
| Didanosine | 11 | 2010 | 151 | 0.580 |
Why?
|
| Stavudine | 7 | 2012 | 84 | 0.570 |
Why?
|
| Clinical Trials as Topic | 19 | 2016 | 7996 | 0.560 |
Why?
|
| HIV Protease | 11 | 2009 | 97 | 0.560 |
Why?
|
| DNA, Circular | 2 | 2015 | 97 | 0.540 |
Why?
|
|